The substantial cost reductions and influx of cash improve Lexicon's financial runway, reducing near-term dilution risk. Positive regulatory feedback on pilavapadin and progress in pivotal trials for sotagliflozin represent key upcoming catalysts. Traders should monitor enrollment progress in the SONATA-HCM trial and timing of the NDA resubmission for T1D.
LXRX drugs
LXRX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $1.64entry
- T+1 · 9mo ago +4.27%α +5.58% · $1.71
- T+5 · 8mo ago +4.88%α +7.12% · $1.72
- T+20 · 8mo ago −3.05%α +0.74% · $1.59
- T+60 · 6mo ago +26.22%α +14.92% · $2.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lexicon Pharmaceuticals reported Q4 2025 financial results with $5.5 million in revenue, driven by licensing income from Novo Nordisk and INPEFA sales. The company reduced R&D and SG&A expenses significantly year-over-year, cutting its net loss by over half. It also strengthened its balance sheet with $106.7 million in new cash from a stock sale and a milestone payment. Key pipeline progress includes advancing sotagliflozin for HCM and T1D, and preparing pilavapadin for Phase 3 trials in neuropathic pain.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $5.5 million, down from $26.6 million in Q4 2024 (primarily due to a $25M upfront payment from Viatris in 2024)
- Net loss narrowed to $15.5 million in Q4 2025 from $33.8 million in Q4 2024
- Full-year 2025 net loss was $50.3 million, a 75% improvement from $200.4 million in 2024
- Received $106.7 million in new cash in February 2026 ($96.7M from stock sale, $10M milestone from Novo Nordisk)
- Cash, investments, and restricted cash totaled $125.2 million as of December 31, 2025
- R&D expenses decreased to $11.3 million in Q4 2025 from $26.7 million in Q4 2024
- SG&A expenses decreased to $8.8 million in Q4 2025 from $32.3 million in Q4 2024
- SONATA-HCM Phase 3 trial is over 50% enrolled, with completion expected mid-2026
- Positive End-of-Phase 2 meeting with FDA for pilavapadin supports advancement to Phase 3
- NDA resubmission for sotagliflozin in T1D targeted for 2026
Financial Impact
Reduced annual net loss by $150.1 million year-over-year and added $106.7 million in new cash, significantly extending runway for clinical development
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| INPEFA | $1.1M | -31.9% |
Risk Factors
- Revenue decline reflects absence of large upfront payments; sustainable commercial growth from INPEFA remains limited ($1.1M in Q4)
- Future milestones and regulatory approvals are not guaranteed, particularly for sotagliflozin in T1D and pilavapadin in Phase 3
- High reliance on partnership funding (Novo Nordisk) for LX9851 development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001062822-26-000047 |
| Document: lxrx-20260305.htm | 0001062822-26-000047 |
| Document: 0001062822-26-000047-index-headers.html | 0001062822-26-000047 |
| Document: 0001062822-26-000047-index.html | 0001062822-26-000047 |
| Document: 0001062822-26-000047.txt | 0001062822-26-000047 |
Track record
16 reports on LXRX
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 No price data
- Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
- May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
- Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers